Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (7)
  • Open Access

    ARTICLE

    Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma

    LISANNE K.A. NEIJENHUIS1,2,3,#, LEUTA L. NAUMANN4,#, SONIA A.M. FERKEL1, SAMUEL J.S. RUBIN1, STEPHAN ROGALLA1,*

    Oncology Research, Vol.32, No.7, pp. 1163-1172, 2024, DOI:10.32604/or.2024.050907

    Abstract Background: Osteosarcoma is the most common malignant primary bone tumor. The prognosis for patients with disseminated disease remains very poor despite recent advancements in chemotherapy. Moreover, current treatment regimens bear a significant risk of serious side effects. Thus, there is an unmet clinical need for effective therapies with improved safety profiles. Taurolidine is an antibacterial agent that has been shown to induce cell death in different types of cancer cell lines. Methods: In this study, we examined both the antineoplastic and antiangiogenic effects of taurolidine in animal models of osteosarcoma. K7M2 murine osteosarcoma cells were… More >

  • Open Access

    REVIEW

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

    QIUQIANG CHEN1,*, XUEJUN GUO2, WENXUE MA3,*

    Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383

    Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy… More > Graphic Abstract

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

  • Open Access

    REVIEW

    Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment

    ABHISHEK WAHI1, MAMTA BISHNOI2, NEHA RAINA1, MEGHNA AMRITA SINGH1, PIYUSH VERMA1, PIYUSH KUMAR GUPTA3,4, GINPREET KAUR5, HARDEEP SINGH TULI6,*, MADHU GUPTA1,*

    Oncology Research, Vol.32, No.1, pp. 19-47, 2024, DOI:10.32604/or.2023.042228

    Abstract Cancer is a leading cause of death globally, with limited treatment options and several limitations. Chemotherapeutic agents often result in toxicity which long-term conventional treatment. Phytochemicals are natural constituents that are more effective in treating various diseases with less toxicity than the chemotherapeutic agents providing alternative therapeutic approaches to minimize the resistance. These phytoconstituents act in several ways and deliver optimum effectiveness against cancer. Nevertheless, the effectiveness of phyto-formulations in the management of cancers may be constrained due to challenges related to inadequate solubility, bioavailability, and stability. Nanotechnology presents a promising avenue for transforming current… More > Graphic Abstract

    Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment

  • Open Access

    REVIEW

    Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

    DHANYA K. NAMBIAR1, DEEPALI MISHRA2, RANA P. SINGH2,3,*

    Oncology Research, Vol.31, No.4, pp. 405-421, 2023, DOI:10.32604/or.2023.028310

    Abstract Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical More > Graphic Abstract

    Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

  • Open Access

    STUDY PROTOCOL IN FRENCH

    Impact of Adapted Physical Activity on Joint Pain Induced by Hormonotherapy in Adjuvant Breast Cancer Treatment: APAISE Study Protocol
    Impact de l’Activité Physique Adaptée sur les Douleurs Articulaires Induites sous Hormonothérapie en Traitement Adjuvant du Cancer : Protocole de l’Etude APAISE

    Virginie Prevost1,2,#,*, Pauline Drillon3,#, Antoine Desvergée4, Corinne Delcambre2, Claire Delorme2, Anne Besnier5, Kévin Lecaplain6, Charline Frandemiche7, Anaïs Briant7, Rémy Morello4, Xavier Blaizot7

    Oncologie, Vol.24, No.3, pp. 357-369, 2022, DOI:10.32604/oncologie.2022.025107

    Abstract Breast cancer is the most common cancer in women and approximately 80% of patients will receive hormone therapy. If survival rate after breast cancer patients is the most important, their treatment, induces strong side effects on quality of life, including joint pain which is encountered by one woman in two. These joint pains are likely to reduce compliance with the treatment and consequently impact survival. In this context, this work aims to evaluate the potential benefit of adapted physical activity to relieve pain and its impact on daily functions. The APAISE protocol, described in this… More >

  • Open Access

    ARTICLE

    Long noncoding RNA LINC01124 activates hepatocellular carcinoma cell proliferation, migration, and invasion by absorbing microRNA-1247-5p and overexpressing FOXO3

    LEI SUN1,2, YUE ZHANG3, YUQIN YAO4, HONGLIN DU3, YUEHUA ZHANG1, AIPING FANG1,2,*

    Oncology Research, Vol.29, No.3, pp. 175-187, 2021, DOI:10.32604/or.2022.03550

    Abstract Long intergenic non-protein coding RNA 1124 (LINC01124) has been identified as an important regulator of non-small-cell lung cancer. However, the expression and detailed role of LINC01124 in hepatocellular carcinoma (HCC) remain unestablished to date. Therefore, this study aimed to elucidate the role of LINC01124 in the aggressiveness of HCC cells and identify the underlying regulatory mechanism. Quantitative reverse transcriptase-polymerase chain reaction was performed to measure the expression of LINC01124 in HCC. Cell Counting Kit-8 assay, Transwell cell migration and invasion assays, and a xenograft tumor model were used to investigate the function of LINC01124 in… More >

  • Open Access

    ARTICLE

    Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment

    Pedro Fong*1, Cheng N. Ao*†1, Kai I. Tou*, Ka M. Huang*, Chi C. Cheong*, Li R. Meng*

    Oncology Research, Vol.27, No.2, pp. 237-251, 2019, DOI:10.3727/096504018X15235274183790

    Abstract The aim of this study was to investigate the inhibition effects of cordycepin and its derivatives on endometrial cancer cell growth. Cytotoxicity MTT assays, clonogenic assays, and flow cytometry were used to observe the effects on apoptosis and regulation of the cell cycle of Ishikawa cells under various concentrations of cordycepin, cisplatin, and combinations of the two. Validated in silico docking simulations were performed on 31 cordycepin derivatives against adenosine deaminase (ADA) to predict their binding affinities and hence their potential tendency to be metabolized by ADA. Cordycepin has a significant dose-dependent inhibitory effect on More >

Displaying 1-10 on page 1 of 7. Per Page